本帖最后由 老马 于 2012-1-13 21:20 编辑
5 P, H; K; n* i
2 {; U1 q9 e) Z0 K爱必妥和阿瓦斯丁的比较; k* O Q! _0 }
$ ~ E& d# r, Q2 g" A$ dhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
( L9 q9 A! U6 h
4 s- E, N, k; }5 r: }! @
n. J9 Y( @" c- G7 ^http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/ M0 W0 x4 G, d
==================================================
2 B: f/ L! D5 j$ e$ | X$ c6 \Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)4 D4 ^) n0 E1 Q2 c
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
2 q( ]! L. v1 k wResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
* j3 v x8 J$ f$ m
|